Discover trends, market shifts, and competitive outlooks for the non-alcoholic steatohepatitis treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Non-Alcoholic Steatohepatitis Treatment Market In 2029?

Over recent years, there has been a significant increase in the market size for non-alcoholic steatohepatitis (NASH) treatments. It is projected to expand from $2.6 billion in 2024 to approximately $3.6 billion in 2025, reflecting a compound annual growth rate (CAGR) of 38.5%. Factors such as the increasing instances of NASH, enhanced awareness and diagnostic procedures, changes in lifestyle and an obesity crisis, advancements in clinical research, improved healthcare facilities and accessibility, regulatory backing and clinical trials have all contributed to the growth witnessed during this historical period.

The market size for non-alcoholic steatohepatitis treatment is set to experience significant growth in the coming years, reaching $13.83 billion with a compound annual growth rate (CAGR) of 40.0% by 2029. The surge in the projected period is due to progress in drug improvement, heightened awareness of the disease, an increased prevalence and risk factor, along with a shift towards personalized medicine. Key trends in the forecast period involve focusing on the patient’s needs, breakthroughs in technology, specific therapies, regulatory environment, and research advancements.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Non-Alcoholic Steatohepatitis Treatment Market?

The rising incidence of insulin resistance is driving the growth of the non-alcoholic steatohepatitis treatment market. Insulin resistance happens when cells from muscle, fat, and the liver don’t respond properly to insulin, making it harder for them to use glucose from the bloodstream, leading to high blood sugar. This condition is generally associated with unhealthy lifestyles, excessive sugar intake, and genetic predisposition. As diabetes and related liver disorders have surged, so too has the occurrence of insulin resistance, creating a greater need for non-alcoholic steatohepatitis treatments. For instance, a January 2022 report from the Belgium-based International Diabetes Federation disclosed that diabetes impacts 537 million people aged 20-79 – equating to one in ten individuals. It’s projected to surge to 643 million by 2030 and reach 783 million by 2045. Furthermore, the American Cancer Society, a US-based cancer advocacy organization, predicted in January 2024 that new cases of liver cancer will increase to 41,630 in 2024, representing a rise from 41,210 in 2023. Hence, escalating instances of insulin resistance due to growing prevalence of diabetes and liver-related conditions will inevitably spur the non-alcoholic steatohepatitis treatment market.

What Segment Types Define the Non-Alcoholic Steatohepatitis Treatment Market Structure?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Non-Alcoholic Steatohepatitis Treatment Market?

The evolution of non-alcoholic steatohepatitis (NASH) medication is an emerging trend in the NASH treatment market. Several businesses are plowing resources into the creation of novel drugs for liver disease treatment with fewer drug side effects. For example, Pfizer Inc., an American pharmaceutical and biotech firm, was granted a fast-track designation by the U.S. Food and Drug Administration (FDA) in May 2022, to expedite the development of a NASH drug, specifically ervogastat and clesacostat. This fast track designation is aimed at accelerating the development of Pfizer’s investigative combination therapy for NASH with liver fibrosis. The specific drugs involved are ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Is the Definition of the Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model